Bone biologics announces exercise of warrants for $2.1 million gross proceeds

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in march 2024. the issuance of the shares of common stock issuable upon exerc.
BBLG Ratings Summary
BBLG Quant Ranking